BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 28917596)

  • 21. Prognostic model in patients with metastatic urothelial carcinoma receiving immune checkpoint inhibitors after platinum failure.
    Park JH; Park I; Kim IH; Hur JY; Hwang I; Kim C; Kim HJ; Maeng CH; Park K; Lee MY; Lee HJ; Jung JY; Keam B; Park SH; Lee JL
    Curr Probl Cancer; 2022 Jun; 46(3):100848. PubMed ID: 35344842
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Systemic treatments for metastatic urothelial carcinoma.
    Lalani AA; Sonpavde GP
    Expert Opin Pharmacother; 2019 Feb; 20(2):201-208. PubMed ID: 30412003
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial.
    Petrylak DP; de Wit R; Chi KN; Drakaki A; Sternberg CN; Nishiyama H; Castellano D; Hussain S; Fléchon A; Bamias A; Yu EY; van der Heijden MS; Matsubara N; Alekseev B; Necchi A; Géczi L; Ou YC; Coskun HS; Su WP; Hegemann M; Percent IJ; Lee JL; Tucci M; Semenov A; Laestadius F; Peer A; Tortora G; Safina S; Del Muro XG; Rodriguez-Vida A; Cicin I; Harputluoglu H; Widau RC; Liepa AM; Walgren RA; Hamid O; Zimmermann AH; Bell-McGuinn KM; Powles T;
    Lancet; 2017 Nov; 390(10109):2266-2277. PubMed ID: 28916371
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Real-world sequential treatment patterns and clinical outcomes among patients with advanced urothelial carcinoma in Japan.
    Kita Y; Otsuka H; Ito K; Hara T; Shimura S; Kawahara T; Kato M; Kanamaru S; Inoue K; Ito H; Igarashi A; Sazuka T; Takamatsu D; Hashimoto K; Abe T; Naito S; Matsui Y; Nishiyama H; Kitamura H; Kobayashi T;
    Int J Urol; 2024 May; 31(5):552-559. PubMed ID: 38303567
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Management of metastatic urothelial carcinoma: Current approach, emerging agents, and future perspectives.
    Iacovelli R; Cicala CM; Ciccarese C; Sacco E; Racioppi M; Bassi PF; Tortora G
    Urologia; 2023 Feb; 90(1):3-10. PubMed ID: 36537831
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic Value of Fibroblast Growth Factor Receptor Genetic Alterations in Metastatic Urothelial Carcinoma.
    Fleming S; Gifkins D; Resnick HE; Shalaby W; Rosenberg P; Gaj C; Maio V; Crawford A; Lu-Yao G; Gao J; Siefker-Radtke A
    Clin Genitourin Cancer; 2024 Jun; 22(3):102054. PubMed ID: 38457853
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Predictors of Efficacy of Immune Checkpoint Inhibitors in Patients With Advanced Urothelial Carcinoma: A Systematic Review and Meta-Analysis.
    Ferro M; Crocetto F; Tataru S; Barone B; Dolce P; Lucarelli G; Sonpavde G; Musi G; Antonelli A; Veccia A; Terracciano D; Busetto GM; Del Giudice F; Marchioni M; Schips L; Porpiglia F; Fiori C; Carrieri G; Lasorsa F; Verde A; Scafuri L; Buonerba C; Di Lorenzo G
    Clin Genitourin Cancer; 2023 Oct; 21(5):574-583. PubMed ID: 37419854
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A review of the PD-1/PD-L1 checkpoint in bladder cancer: From mediator of immune escape to target for treatment.
    Zhou TC; Sankin AI; Porcelli SA; Perlin DS; Schoenberg MP; Zang X
    Urol Oncol; 2017 Jan; 35(1):14-20. PubMed ID: 27816403
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Retrospective analysis of satraplatin in patients with metastatic urothelial cancer refractory to standard platinum-based chemotherapy.
    Galsky MD; Seng S; Camacho LH; Chiorean EG; Mulkerin D; Hong DS; Oh WK; Bajorin DF
    Clin Genitourin Cancer; 2011 Sep; 9(1):27-30. PubMed ID: 21700509
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immune Checkpoint Inhibitors in Front-line Therapy for Urothelial Cancer.
    Szabados B; Prendergast A; Jackson-Spence F; Choy J; Powles T
    Eur Urol Oncol; 2021 Dec; 4(6):943-947. PubMed ID: 33811019
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Real-World Analysis of Treatment Patterns and Platinum-Based Treatment Eligibility of Patients With Metastatic Urothelial Cancer in 5 European Countries.
    Milloy N; Kirker M; Unsworth M; Montgomery R; Kluth C; Kearney M; Chang J
    Clin Genitourin Cancer; 2024 Feb; 22(1):e136-e147.e1. PubMed ID: 37945404
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Current Therapy for Metastatic Urothelial Carcinoma.
    Nadal R; Clara JA; Valderrama BP; Bellmunt J
    Hematol Oncol Clin North Am; 2021 Jun; 35(3):469-493. PubMed ID: 33958146
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Salvage systemic therapy for metastatic urothelial carcinoma: an unmet clinical need.
    Montazeri K; Sonpavde G
    Expert Rev Anticancer Ther; 2021 Mar; 21(3):299-313. PubMed ID: 33249937
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Atezolizumab (Tecentriq
    Bernard-Tessier A; Bonnet C; Lavaud P; Gizzi M; Loriot Y; Massard C
    Bull Cancer; 2018 Feb; 105(2):140-145. PubMed ID: 29290331
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Advances in the management of urothelial carcinoma: is immunotherapy the answer?
    Santopietro AL; Einstein D; Bellmunt J
    Expert Opin Pharmacother; 2021 Sep; 22(13):1743-1759. PubMed ID: 33905290
    [No Abstract]   [Full Text] [Related]  

  • 36. Durvalumab for the treatment of urothelial carcinoma.
    Alsharedi M; Srivastava R; Elmsherghi N
    Drugs Today (Barc); 2017 Dec; 53(12):647-652. PubMed ID: 29517083
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Avelumab for the treatment of urothelial cancer.
    Rodriguez-Vida A; Bellmunt J
    Expert Rev Anticancer Ther; 2018 May; 18(5):421-429. PubMed ID: 29540084
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Atezolizumab in invasive and metastatic urothelial carcinoma.
    Crist M; Balar A
    Expert Rev Clin Pharmacol; 2017 Dec; 10(12):1295-1301. PubMed ID: 28994323
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role of Checkpoint Inhibition in Localized Bladder Cancer.
    Hahn NM; Necchi A; Loriot Y; Powles T; Plimack ER; Sonpavde G; Roupret M; Kamat AM
    Eur Urol Oncol; 2018 Aug; 1(3):190-198. PubMed ID: 31102620
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Activation of the DDR Pathway Leads to the Down-Regulation of the TGFβ Pathway and a Better Response to ICIs in Patients With Metastatic Urothelial Carcinoma.
    Zhou C; Lin A; Cao M; Ding W; Mou W; Guo N; Chen Z; Zhang J; Luo P
    Front Immunol; 2021; 12():634741. PubMed ID: 34220801
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.